Knowledge sharing expertise firm Datavant has expanded its collaboration with pharmaceutical firm Boehringer Ingelheim to help Boehringer’s real-world proof initiatives.
The prolonged collaboration goals to leverage Datavant’s privacy-preserving tokenization and information connectivity applied sciences to strengthen medical growth and provoke methods throughout 75 further medical trials and a number of new molecular entities.
By way of Datavant Join, a platform that helps stability information utility with information privateness, Boehringer can adeptly discover and consider third-party information sources with out shifting or sharing underlying information.
By making use of Datavant’s expertise throughout a broad portfolio of trials and launches, Boehringer Ingelheim goals to extend the mixing of real-world information into drug growth.
Moreover, groups will implement tokenization in a phased rollout to make sure seamless integration with Boehringer Ingelheim’s current analysis infrastructure.
Arnaub Chatterjee, common supervisor and president, life sciences, ecosystem and public sector for Datavant, mentioned by enabling safe and environment friendly information linkage at scale, Boehringer Ingelheim is establishing a brand new benchmark for medical analysis.
“This partnership exemplifies how expertise can reshape healthcare and enhance affected person outcomes,” Chatterjee mentioned in an announcement.
Paul Petraro, govt director and head of the actual world proof analytics heart of excellence for Boehringer Ingelheim, mentioned funding in real-world information underscores Boehringer Ingelheim’s dedication to utilizing cutting-edge applied sciences to advance medical analysis.
“By increasing this method throughout extra trials and business launches, we’re positioned to drive extra personalised and cost-effective therapies, in the end reworking affected person care,” Petraro mentioned in an announcement.
THE LARGER TREND
In 2023, Socially Decided partnered with Datavant to offer life sciences corporations with information on social danger drivers to enhance well being fairness and affected person outcomes.
Socially Decided makes use of information to supply insights into the social determinants of well being, together with components like entry to meals, housing and transportation.
In 2021, psychedelic-inspired biotech firm MindMed tapped Datavant to assist hyperlink its medical trial information with exterior proof from different medical trials and real-world information sources.
Utilizing Datavant’s privacy-protecting expertise, MindMed created datasets to know the real-world remedy, service utilization and healthcare experiences of sufferers with psychiatric and substance use issues. By rising its information, MindMed hoped to higher develop its product pipeline.
In 2020, Datavant closed $40 million in Sequence B funding. Transformation Capital led the elevate, which noticed contributions from new backers Johnson & Johnson Innovation – JJDC and Cigna Ventures and current traders Roivant Sciences and Flex Capital.
In 2023, Boehringer Ingelheim and tech large IBM teamed as much as harness the ability of generative AI and basis fashions to additional biologic drug discovery.
The partnership leveraged IBM’s basis mannequin applied sciences, consisting of pre-trained, large-scale neural community architectures, to speed up the identification of novel antibodies important for therapeutic growth.
That very same yr, Boehringer Ingelheim and digital therapeutic firm Click on Therapeutics initiated a medical trial known as CONVOKE Research, which evaluated prescription digital therapeutics as an adjunct remedy for schizophrenia.
The randomized trial included 432 contributors and in contrast prescription digital therapeutics to the usual of care utilizing antipsychotic remedy over the course of 16 weeks.
Source link
